General Information of the Drug (ID: M6APDG03951)
Name
BPI-9016 M
Status
Phase 1
TTD Drug ID
D95YSW
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Proto-oncogene c-Met (MET)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
Response Summary Proto-oncogene c-Met (MET) is a therapeutic target for BPI-9016 M. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BPI-9016 M through regulating the expression of Proto-oncogene c-Met (MET). [1], [2]
Tyrosine-protein kinase UFO (AXL)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
Response Summary Tyrosine-protein kinase UFO (AXL) is a therapeutic target for BPI-9016 M. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BPI-9016 M through regulating the expression of Tyrosine-protein kinase UFO (AXL). [3], [4]
RNA demethylase ALKBH5 (ALKBH5)
In total 1 mechanisms lead to this potential drug response
Response Summary Tyrosine-protein kinase UFO (AXL) is a therapeutic target for BPI-9016 M. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of BPI-9016 M through regulating the expression of Tyrosine-protein kinase UFO (AXL). [4], [5]
References
Ref 1 RNA m(6) A methylation regulates uveal melanoma cell proliferation, migration, and invasion by targeting c-Met. J Cell Physiol. 2020 Oct;235(10):7107-7119. doi: 10.1002/jcp.29608. Epub 2020 Feb 4.
Ref 2 Clinical pipeline report, company report or official report of Exelixis.
Ref 3 METTL3 promotes ovarian carcinoma growth and invasion through the regulation of AXL translation and epithelial to mesenchymal transition. Gynecol Oncol. 2018 Nov;151(2):356-365. doi: 10.1016/j.ygyno.2018.09.015. Epub 2018 Sep 21.
Ref 4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 5 Leukemogenic Chromatin Alterations Promote AML Leukemia Stem Cells via a KDM4C-ALKBH5-AXL Signaling Axis. Cell Stem Cell. 2020 Jul 2;27(1):81-97.e8. doi: 10.1016/j.stem.2020.04.001. Epub 2020 May 12.